Glomerular Disease

Glomerular disease is a type of kidney disease in which the part of your kidneys that helps filter waste and fluids from the blood is damaged.

Programs + Services


Kidney and Blood Pressure Center

The Tufts MC Kidney and Blood Pressure Center provides both one-time consultations and ongoing care for chronic or acute kidney disease and high blood pressure.
More information about programs and services

Doctors + Care Team

Ronald D. Perrone, MD

Ronald D. Perrone, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Scientific Director, Clinical and Translational Research Center; Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology, Clinical and Translational Research Center (CTRC)
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Polycystic kidney disease (PKD)

View Full Profile for Ronald D. Perrone, MD

Mark J. Sarnak, MD, MS

Mark J. Sarnak, MD, MS

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Division of Nephrology; Director, Research Training Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Dialysis, general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Mark J. Sarnak, MD, MS

Scott J. Gilbert, MD

Scott J. Gilbert, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Fellowship Training Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Kidney transplantation, systemic lupus erythematosus, dialysis, general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Scott J. Gilbert, MD

Lesley A.  Inker, MD, MS

Lesley A. Inker, MD, MS

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Kidney and Blood Pressure Center; Director, Kidney Function and Evaluation Center; Director, Quality Improvement; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Geriatric nephrology, pregnancy, HIV-associated kidney disease, kidney transplantation, kidney donor evaluation, medical treatment for kidney failure without dialysis, kidney function evaluation (GFR), general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Lesley A. Inker, MD, MS

Amy Kuhlik, MD

Amy Kuhlik, MD

Accepting New Patients

Title(s): Nephrologist; Dean for Student Affairs and Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Pregnancy, general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Amy Kuhlik, MD

Andrew S. Levey, MD

Andrew S. Levey, MD

Loading ...

Virtual Appointments Available

Title(s): Chief Emeritus, Division of Nephrology; Professor of Medicine, Tufts University School of Medicine; Dr. Gerald J and Dorothy R. Friedman Professor Emeritus, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Kidney function evaluation (GFR), chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, systemic lupus erythematosus, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Andrew S. Levey, MD

Klemens B. Meyer, MD

Klemens B. Meyer, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Medical Director, Dialysis Clinic, Inc., Boston and Walden Pond, Concord, MA; Director Dialysis Services, Tufts Medical Center; Medical Director for Home Dialysis, Dialysis Clinics, Inc, Somerville, MA; Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-5539

Dialysis, home dialysis, medical treatment for kidney failure without dialysis, general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Klemens B. Meyer, MD

Dana C. Miskulin, MD, MS

Dana C. Miskulin, MD, MS

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Nephrologist; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Nephrology
Appt. Phone: 617-636-5866
Fax #: 617-636-2369

Polycystic kidney disease (PKD), dialysis, home dialysis, general nephrology, chronic kidney disease (CKD), diabetic kidney disease, glomerular disease, vasculitis, hypertension, cardiovascular disease in patients with kidney disease, acute kidney disease, acute kidney injury and kidney stones

View Full Profile for Dana C. Miskulin, MD, MS

Research + Clinical Trials


The AFFINITY Study: A trial for patients with kidney disease caused by Focal Segmental Glomerulosclerosis (FSGS), Immunoglobulin A (IgA) Nephropathy, Diabetic Kidney Diseases (DKD), or Alport Syndrome. 

The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome. 

The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year. 
More information about research and clinical trials


A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)

Primary Objectives:

• Evaluate the safety and tolerability of sparsentan oral suspension

• Assess changes in proteinuria after once-daily dosing of sparsentan oral suspension over the 108-week treatment period

 

Secondary Objectives:

• Assess the pharmacokinetics (PK) of sparsentan oral suspension in a pediatric population

• Assess changes in estimated glomerular filtration rate (eGFR) after once-daily dosing of sparsentan oral suspension over the 108-week treatment period

 

Exploratory Objective:

• Assess the palatability and acceptability of sparsentan oral suspension

 

Primary Endpoints:

• Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to treatment discontinuation, and adverse events of interest (AEOIs)

• Change from baseline in urine protein/creatinine ratio (UP/C) over the 108-week treatment period

Secondary Endpoints:

• Observed plasma PK concentrations at scheduled timepoints and visits

• Steady-state PK parameters (area under the plasma concentration-time curve during a dosing interval [AUCτ], maximum steady-state plasma drug concentration during a dosage interval [Cmax_ss], and minimum steady-state plasma drug concentration [Cmin_ss]) derived from population PK analysis

• Change from baseline in urine albumin/creatinine ratio (UA/C) over the 108-week treatment period

• Change from baseline in eGFR over the 108-week treatment period

• The proportion of subjects with focal segmental glomerulosclerosis (FSGS) and/or minimal change disease (MCD) histological patterns achieving partial remission, defined as UP/C ≤1.5 g/g and >40% reduction in UP/C over the 108-week treatment period


More information about research and clinical trials